Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alnylam Pharmaceuticals (ALNY) has issued an update.
Alnylam Pharmaceuticals has finalized a separation and release agreement with its former Executive Vice President, Indrani L. Franchini, effective March 1, 2024. Franchini will receive severance pay, a lump sum equivalent to her potential 2023 annual incentive, healthcare premium contributions, outplacement services, and legal fee reimbursement. Additionally, she has entered a one-year consulting contract with the company, during which her unvested equity will continue to vest, and she will be compensated for any extra consulting hours. Her equity awards will also align with active employees’ terms in case of a company control change.
Find detailed analytics on ALNY stock on TipRanks’ Stock Analysis page.
